These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 24399849)

  • 1. Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer.
    Liu NQ; Stingl C; Look MP; Smid M; Braakman RB; De Marchi T; Sieuwerts AM; Span PN; Sweep FC; Linderholm BK; Mangia A; Paradiso A; Dirix LY; Van Laere SJ; Luider TM; Martens JW; Foekens JA; Umar A
    J Natl Cancer Inst; 2014 Feb; 106(2):djt376. PubMed ID: 24399849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer.
    Liu YR; Jiang YZ; Xu XE; Hu X; Yu KD; Shao ZM
    Clin Cancer Res; 2016 Apr; 22(7):1653-62. PubMed ID: 26813360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery.
    Park YH; Jung HH; Do IG; Cho EY; Sohn I; Jung SH; Kil WH; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH
    Int J Cancer; 2015 Apr; 136(8):1976-84. PubMed ID: 25537444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Re: Comparative proteome analysis revealing an 11-protein signature for aggressive triple-negative breast cancer.
    Bakinde N; Gbolahan O; Ibraheem A
    J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25265941
    [No Abstract]   [Full Text] [Related]  

  • 5. A novel prognostic two-gene signature for triple negative breast cancer.
    Alsaleem MA; Ball G; Toss MS; Raafat S; Aleskandarany M; Joseph C; Ogden A; Bhattarai S; Rida PCG; Khani F; Davis M; Elemento O; Aneja R; Ellis IO; Green A; Mongan NP; Rakha E
    Mod Pathol; 2020 Nov; 33(11):2208-2220. PubMed ID: 32404959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer.
    Yu KD; Zhu R; Zhan M; Rodriguez AA; Yang W; Wong S; Makris A; Lehmann BD; Chen X; Mayer I; Pietenpol JA; Shao ZM; Symmans WF; Chang JC
    Clin Cancer Res; 2013 May; 19(10):2723-33. PubMed ID: 23549873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER).
    Bueno-de-Mesquita JM; van Harten WH; Retel VP; van 't Veer LJ; van Dam FS; Karsenberg K; Douma KF; van Tinteren H; Peterse JL; Wesseling J; Wu TS; Atsma D; Rutgers EJ; Brink G; Floore AN; Glas AM; Roumen RM; Bellot FE; van Krimpen C; Rodenhuis S; van de Vijver MJ; Linn SC
    Lancet Oncol; 2007 Dec; 8(12):1079-1087. PubMed ID: 18042430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A serum microRNA signature predicts tumor relapse and survival in triple-negative breast cancer patients.
    Kleivi Sahlberg K; Bottai G; Naume B; Burwinkel B; Calin GA; Børresen-Dale AL; Santarpia L
    Clin Cancer Res; 2015 Mar; 21(5):1207-14. PubMed ID: 25547678
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Highly heterogeneous-related genes of triple-negative breast cancer: potential diagnostic and prognostic biomarkers.
    Liu Y; Teng L; Fu S; Wang G; Li Z; Ding C; Wang H; Bi L
    BMC Cancer; 2021 May; 21(1):644. PubMed ID: 34053447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of Recurrence and Survival for Triple-Negative Breast Cancer (TNBC) by a Protein Signature in Tissue Samples.
    Campone M; Valo I; Jézéquel P; Moreau M; Boissard A; Campion L; Loussouarn D; Verriele V; Coqueret O; Guette C
    Mol Cell Proteomics; 2015 Nov; 14(11):2936-46. PubMed ID: 26209610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.
    Abdel-Fatah TM; McArdle SE; Agarwal D; Moseley PM; Green AR; Ball GR; Pockley AG; Ellis IO; Rees RC; Chan SY
    Clin Cancer Res; 2016 Feb; 22(4):905-14. PubMed ID: 26240276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer.
    Criscitiello C; Bayar MA; Curigliano G; Symmans FW; Desmedt C; Bonnefoi H; Sinn B; Pruneri G; Vicier C; Pierga JY; Denkert C; Loibl S; Sotiriou C; Michiels S; André F
    Ann Oncol; 2018 Jan; 29(1):162-169. PubMed ID: 29077781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.
    Gasparini P; Cascione L; Fassan M; Lovat F; Guler G; Balci S; Irkkan C; Morrison C; Croce CM; Shapiro CL; Huebner K
    Oncotarget; 2014 Mar; 5(5):1174-84. PubMed ID: 24632568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.
    Sharma P; Barlow WE; Godwin AK; Parkes EE; Knight LA; Walker SM; Kennedy RD; Harkin DP; Logan GE; Steele CJ; Lambe SM; Badve S; Gökmen-Polar Y; Pathak HB; Isakova K; Linden HM; Porter P; Pusztai L; Thompson AM; Tripathy D; Hortobagyi GN; Hayes DF
    J Clin Oncol; 2019 Dec; 37(36):3484-3492. PubMed ID: 31657982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship between nuclear factor (NF)-κB family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment.
    Kim JY; Jung HH; Ahn S; Bae S; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
    Sci Rep; 2016 Aug; 6():31804. PubMed ID: 27545642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A gene signature predicts response to neoadjuvant chemotherapy in triple-negative breast cancer patients.
    Zheng T; Pang Z; Zhao Z
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 30988073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics.
    Gámez-Pozo A; Trilla-Fuertes L; Prado-Vázquez G; Chiva C; López-Vacas R; Nanni P; Berges-Soria J; Grossmann J; Díaz-Almirón M; Ciruelos E; Sabidó E; Espinosa E; Fresno Vara JÁ
    PLoS One; 2017; 12(6):e0178296. PubMed ID: 28594844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
    Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
    PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of triple-negative breast cancer radiosensitive gene signature and validation based on transcriptome analysis.
    Wushou A; Jiang YZ; Hou J; Liu YR; Guo XM; Shao ZM
    Breast Cancer Res Treat; 2015 Nov; 154(1):57-62. PubMed ID: 26476726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of ERBB4 expression in patients with triple negative breast cancer.
    Kim JY; Jung HH; Do IG; Bae S; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Park YH; Im YH
    BMC Cancer; 2016 Feb; 16():138. PubMed ID: 26907936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.